Journal
NATURE
Volume 572, Issue 7769, Pages 392-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41586-019-1456-0
Keywords
-
Categories
Funding
- Virginia D. K. Ludwig Fund for Cancer Research [NIHR01CA086017, NIHGR01GM100315]
- NIH/NCI Outstanding Investigator Award [R35CA220434]
- Stanford Medical Scientist Training Program [T32GM007365]
- National Cancer Institute [F30CA232472]
- Program in Translational and Experimental Hematology T32 from the National Heart, Lung, and Blood Institute [1T32HL120824]
Ask authors/readers for more resources
Ovarian cancer and triple-negative breast cancer are among the most lethal diseases affecting women, with few targeted therapies and high rates of metastasis. Cancer cells are capable of evading clearance by macrophages through the overexpression of antiphagocytic surface proteins called 'don't eat me' signals-including CD471, programmed cell death ligand 1 (PD-L1) 2 and the beta-2 microglobulin subunit of the major histocompatibility class I complex (B2M)(3). Monoclonal antibodies that antagonize the interaction of 'don't eat me' signals with their macrophage-expressed receptors have demonstrated therapeutic potential in several wcancers(4,5). However, variability in the magnitude and durability of the response to these agents has suggested the presence of additional, as yet unknown 'don't eat me' signals. Here we show that CD24 can be the dominant innate immune checkpoint in ovarian cancer and breast cancer, and is a promising target for cancer immunotherapy. We demonstrate a role for tumour-expressed CD24 in promoting immune evasion through its interaction with the inhibitory receptor sialic-acid-binding Ig-like lectin 10 (Siglec-10), which is expressed by tumour-associated macrophages. We find that many tumours overexpress CD24 and that tumour-associated macrophages express high levels of Siglec-10. Genetic ablation of either CD24 or Siglec-10, as well as blockade of the CD24-Siglec-10 interaction using monoclonal antibodies, robustly augment the phagocytosis of all CD24-expressing human tumours that we tested. Genetic ablation and therapeutic blockade of CD24 resulted in a macrophage-dependent reduction of tumour growth in vivo and an increase in survival time. These data reveal CD24 as a highly expressed, anti-phagocytic signal in several cancers and demonstrate the therapeutic potential for CD24 blockade in cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available